Irbesartan, an angiotensin-II inhibitor, has been shown to be an effective antihypertensive agent in clinical trials. The purpose of this study was to assess the costeffectiveness of irbesartan in combination with hydrochlorothiazide (HCTZ) in Swedish health-care setting by predicting clinical events and life years based upon observed reductions in blood pressure in clinical trials. The cost-effectiveness of antihypertensive treatment with irbesartan compared with placebo and to other selected angiotensin-II inhibitors (losartan, valsartan, candesartan) in combination with HCTZ was estimated using a Markov model. The incidence of cardiovascular disease was obtained from the Swedish inpatient registry, whereas the risk reductions associated with antihypertensive therapy were taken from the medical literature. Costs for antihypertensive therapy and for treatment of cardiovascular events were included, and the health effects were measured in terms of qualityadjusted life years (QALYs). The study was conducted from a health-care payer perspective. For a 55-year-old male, irbesartan 150 mg/HCTZ 12.5 mg was a dominant strategy (better health effects at lower costs) when compared with losartan 50 mg/HCTZ 12.5 mg and valsartan 80 mg/HCTZ 12.5 mg, and the cost-effectiveness ratio compared with placebo was h3500 per QALY gained. In moderate-to-severe hypertension, irbesartan was cost-effective compared with losartan, whereas the results compared with candesartan were mixed. Highdose combination therapy of irbesartan was also found to be cost-effective compared with low-dose combination therapy. The results from the model indicate that irbesartan provides a cost-effective antihypertensive treatment strategy compared with both placebo, and to valsartan and losartan.
Introduction
Hypertension is an important risk factor for cardiovascular disease, for example, stroke, coronary heart disease, heart failure and renal damage. 1, 2 Antihypertensive treatment has been found to reduce the risk of cardiovascular diseases in middle-aged and elderly patients with high systolic and/or diastolic blood pressure (BP). [3] [4] [5] Despite improved treatment against hypertension in recent years, many patients remain undiagnosed, undertreated or poorly controlled. 6, 7 The reasons for not reaching the treatment goals may include poor compliance, inadequate choice of antihypertensive medication, insufficient dose or a combination of these factors. 7 Good BP control is particularly needed in high-risk patients, such as patients with severe hypertension or patients with hypertension and additional risk factors such as obesity, diabetes or old age. 3 Clinical trials have shown that antihypertensive treatment with the angiotensin II receptor blocker (ARB) irbesartan is an effective way of lowering the BP, and the side effects are mild. 8 A number of shortterm comparative studies have shown a small but significant advantage for irbesartan in terms of BP reduction when compared with losartan and valsartan. 9 The purpose of this study was to assess the cost-effectiveness of irbesartan in combination with hydrochlorothiazide (HCTZ) in Swedish health-care setting by predicting clinical events and life years through a model-based analysis based upon observed reductions in BP in clinical trials. The comparison was made against placebo, and the other ARBs commonly used in Sweden, that is, losartan, valsartan and candesartan.
Materials and methods

Model structure
The analysis compared irbesartan with three alternative angiotensin-II inhibitors, losartan, valsartan and candesartan, or with placebo. A Markov model with eight health states was constructed in MS Excel: 10 (1) Healthy with hypertension (that is, no history of cardiovascular disease); (2) Myocardial infarction (MI); (3) Post-MI; (4)Angina; (5) Stroke; (6) Post-stroke; (7) Congestive heart failure and (8) All cause mortality. In addition, the patients may undergo revascularization procedures, that is, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, when they are in the MI and angina states. Markov models have been used previously to assess the benefits of antihypertensive therapy. [11] [12] [13] [14] The structure of the Markov model is illustrated in Figure 1 . Each rectangle represents a health state associated with particular costs and quality-of-life values. Each arrow represents a transition from one health state to another, which can occur with a certain probability at yearly intervals. Costs, qualityof-life weights and transition probabilities are all dependent on age and gender. Antihypertensive treatment decreases the risk of cardiovascular events, which in the context of the model means that the transition probabilities for cardiovascular events are reduced. Some simplifications were necessary depending on the availability of epidemiological data. Stroke can for example follow MI, angina or congestive heart failure but not vice versa. Patients with hypertension and coronary artery disease without angina or previous MI were not included. A completely accurate model would require epidemiological data that is not generally available, such as how the risks of recurrent strokes or MIs vary depending on various disease histories.
Estimation of costs
The costs of cardiovascular events were found in official hospital price lists and published cost-ofillness studies. All costs were adjusted to 2007 prices by using the consumer price index for Sweden. The estimates of the costs for angina, heart failure and stroke were taken from Swedish cost-ofillness studies. [15] [16] [17] [18] The costs for stable (h5173) and unstable angina pectoris (h10 701) were taken from Zethraeus et al. 18 and Andersson and Kartman, 16 respectively. These studies are slightly dated, but no recent studies were identified in Swedish settings, and the Diagnose-Related Group (DRG) cost for angina did not accurately reflect the 1-year costs. The 1-year cost for heart failure (h4206) was taken from the recent study by Agvall et al., 15 and the short-and long-term costs for stroke (first year h17 765, subsequent years h5452) were taken from Ghatnekar et al. 17 The costs for MI (h4859), procedures (coronary artery bypass graft: h15 015, percutaneous transluminal coronary angioplasty: h7439) and heart transplantation (h104 332) were taken from the DRG costs. The DRG costs were calculated as an average from 16 hospitals in six different regions of Sweden. [19] [20] [21] [22] [23] [24] The drug costs were taken from the official Swedish pharmaceutical reference book, and are valid as of January 2008. 25 The price per year was h228 for irbesartan 150 mg/HCTZ 12.5 mg, h304 for irbesartan 300 mg/HCTZ 25 mg; h274 for losartan 50 mg/HCTZ 12.5 mg, h428 for losartan 100 mg/ HCTZ 25 mg; h256 for valsartan 80 mg/HCTZ 12.5 mg, h422 for valsartan 160 mg/HCTZ 25 mg and h279 for candesartan 16 mg/HCTZ 12.5 mg.
Estimation of health effects
Depending on the choice of treatment, there will be differences in medication costs and clinical effects. The BP reduction in mm Hg reported in clinical trials does not by itself say much about the health economic benefits. The BP reduction was therefore linked to the outcomes that matter for the patientlonger life and better quality of life-by using the relationship between the BP and the risk of developing cardiovascular disease. In the model, only the risks for the major cardiovascular health states and events have been included, that is, angina pectoris, MI, heart failure and stroke. Post-stroke was assigned a separate health state, as people afflicted by stroke often have quite large costs for care and rehabilitation also in the years after the stroke, and have an increased risk of recurrent strokes. 17 All outcomes were based on predictive modelling rather than observed long-term data. The reduction in BP was linked to the incidence and mortality in cardiovascular disease through risk equations taken from published studies. The duration of the treatment effect was assumed to be 5 years as base case, but the patients were followed for their remaining lifetime (Antihypertensive therapy may often be Figure 1 Overview of the Markov model. CHF, chronic heart failure; HTN, hypertension; MI, myocardial infarction. lifelong, there are few studies of individual antihypertensive therapies that follow patients for a longer time than a few years). This means that the treatment effect was set to a relative risk of one and the medical costs for antihypertensive treatment were set to zero after 5 years. Nevertheless, the treatment choice also plays some role after 5 years in the model, because more people would be alive at 5 years if a more effective treatment was used during the first 5 years. The effect of using different time horizons was explored in the sensitivity analysis.
The main outcome measure was quality-adjusted life years (QALYs). The QALY combines the number of life years and quality of life in one single measure. For example, a year spent in a health state with a quality-of-life weight of 0.8 gives 0.8 QALYs. As patients progress through the model over time, the total number of QALYs will be determined by the total time the patients spend in different health states in the model. As base case, the annual discount rate for costs and health effects was 3%. 26 The outputs from the model are the lifetime costs and the number of expected QALYs. These outputs can then be combined to cost-effectiveness ratios that show the cost per QALY gained for each of the comparators. The threshold used for the willingness to pay per QALY gained was h50 000-60 000. 27 However, the cost-effectiveness ratio is only meaningful if a therapy is more effective and more costly (or, hypothetically, less effective and less costly). A therapy that is both more effective and less costly than another treatment alternative is called 'dominant' compared with the alternative, and the less effective and more costly alternative is thus 'dominated'.
Clinical data sources Literature search. The computerized database MEDLINE (the National Library of Medicine) was used for the literature search. For inclusion, trials had to be randomized and double blind, and use an angiotensin II inhibitor in combination with HCTZ, with either a placebo or active comparator. Trials had to have a minimum of 10 patients per treatment arm, and a planned duration of at least 3 weeks. Potentially useful studies were retrieved in full paper copy. We scanned the references of these papers for further studies, and also scanned the references included in relevant review articles and meta-analyses. The literature search was last updated in January 2008.
Base case-mild-to-moderate hypertension. The base case analysis was based on the BP reductions from Bobrie et al. (COSIMA Study) and Neutel and Smith, 28, 29 and was calculated for a 55-year-old male. The study by Bobrie et al. included patients who were still uncontrolled after a lead-in phase of 5 weeks during which all patients were treated with HCTZ 12.5 mg. 28 The results of the intention-to-treat analysis of the home BP are shown in (candesartan). In terms of age, gender and baseline BP, the three populations were similar, which should make these studies comparable (Table 1 ). In terms of prices, the comparison was made for two cases: irbesartan 150 mg/HCTZ 12.5 mg vs losartan 50 mg/HCTZ 12.5 mg, or irbesartan 300 mg/HCTZ 25 mg vs losartan 100 mg/HCTZ 25 mg. In both cases, candesartan 16 mg/HCTZ 12.5 mg was used in the analysis, as this is the only combination therapy available in Sweden. The reason for analysing the two cases separately is that the patients were uptitrated during the trials, but it is not clear from the publication what the average dosages were in practice.
High-dose/low-dose comparison for irbesartan/ HCTZ combotherapy. Clinical data for the highdose vs low-dose comparison were taken from the INCLUSIVE study. 33 The BP reduction achieved with low-and high-dose irbesartan/HCTZ combination therapy is shown in Table 1 . The trial was designed to test the response to combination therapy in patients who had already failed a minimum of 4 weeks of antihypertensive therapy. Patients achieving BP control on HCTZ monotherapy were thus excluded from the intention-to-treat population.
Risk equations and transition probabilities
In the base case, the risk equations have been taken from the publication of Glynn et al. 34 An advantage of these risk equations is that they include both SBP and DBP. The 5-year risks from the Glynn risk equation were transformed to 1-year risks for use in the Markov model, which has been designed for 1-year cycles.
Transition probabilities between states were derived from gender-and disease-specific tables on the number of patients in each age group that had developed a certain condition in the period 1998-2001. For example, for patients with angina pectoris, Cost-effectiveness of irbesartan in combination with HCTZ M Ekman et al 35 (Supplementary Information on the transition probabilities accompanies the paper on the Journal of Human Hypertension website). The model was validated by comparing predicted incidence and prevalence rates with the literature.
36-41
Base risks As the data on cardiovascular base risks in the model were based on Swedish national inpatient statistics, and epidemiological data, the patients had the average BP levels in the Swedish population. To adjust for this, risk functions from the SCORE project were used to upgrade the risks depending on the initial BP level of the population of interest in the model. 42 The usual SBP in different age groups was taken from a comprehensive Swedish hypertension study. 43 The average SBP levels in the Swedish population were the following: 45-54 years, 131 mm Hg; 55-64 years, 136 mm Hg; 65-74 years, 142 mm Hg and over 75 years, 147 mm Hg.
Health utilities
Health utilities for the different health states were taken from published studies and reviews ( Table 2) . The health utilities for the normal population and for patients with angina pectoris were taken from the population study by Burströ m et al. 44 The publications by Tengs and Lin, 45 and Kirsch and McGuire 46 were used as sources for healthy utilities in stroke and heart failure. In the absence of more specific data, it was assumed that patients with a history of MI had a quality of life similar to patients with angina pectoris.
Sensitivity analyses
In the sensitivity analyses, we looked at uncertain variables and factors, which may affect the costeffectiveness results. We varied the costs of events and the pharmaceutical prices to see how sensitive the results were for variations in the cost inputs. Since losartan will come off patent towards the end of 2009 in Europe, and the other ARBs around 2012, we also looked at a scenario with lower prices after patent expiry. Since the price after patent expiry is as yet unknown, we did not take patent expiry into account in the main analysis, but in the sensitivity analysis we assumed that the price would be equal to the price for enalapril plus, the price for HCTZ, that is, h79 per year for daily treatment. 25 We also looked at the effect of treatment duration, the age at which treatment is initiated, the discount rate for costs and health effects and the effects of using life years gained (LYG) as outcome measure rather than QALYs.
Results
Base case
Irbesartan was cost-effective compared with placebo with a cost-effectiveness ratio of about h3500 per QALY gained for men, and h7700 per QALY gained for women (Table 3 ). Losartan and valsartan were dominated by irbesartan, that is, the total costs are higher and the number of QALYs gained lower.
Severe hypertension
For a patient population with severe hypertension, the analysis was based on the BP reduction for combination therapy in Neutel et al., 30 Salerno et al. 31 and Koenig 32 (Table 1) . Irbesartan was dominant compared with losartan, and cost-effective compared with candesartan for men, but not for women (Table 4 ). We will return to the latter result in the discussion. 
Cost-effectiveness of irbesartan in combination with HCTZ M Ekman et al
High-dose/low-dose comparison for irbesartan/HCTZ combotherapy The cost-effectiveness results for the high-dose/lowdose comparison in Table 5 indicate that high-dose therapy has a cost-effectiveness ratio that is lower than commonly used thresholds (for example, h50 000 per QALY). 27 Sensitivity analyses Cost of events. The cost-effectiveness was found to be relatively sensitive to changes in event costs that are important for the total costs, such as the costs for states that are often long term, for example, stable angina and post-stroke. For a 55-year-old male, for example, the cost-effectiveness ratio decreased by 15% when these events costs were both increased by 20%, and increased by 15% when these events costs were both decreased by 20%. The cost-effectiveness was less sensitive to changes in event costs that were less important for the total costs, such as the cost for acute MI and heart failure. For a 55-year-old male, the cost-effectiveness ratio decreased by 6% when these events costs were both increased by 20%, and increased by 6% when these event costs were both decreased by 20%.
Pharmaceutical prices. The pharmaceutical prices were varied by lowering the prices for losartan, valsartan and candesartan by 20%. In the base case with 55-year-old men, losartan would then still be dominated by irbesartan, and the cost-effectiveness ratio compared with valsartan would be h9720. In 55-year-old women, the cost-effectiveness ratio compared with losartan would be h13 065 per QALY, and compared with valsartan h34 479 per QALY. In the scenario for 55-year-old men with severe hypertension, losartan would then still be dominated by irbesartan, whereas the cost-effectiveness ratio compared with candesartan 16 mg/HCTZ 12.5 mg would be h571 with the price for low-dose therapy, and h105 518 with the price for high-dose therapy. As the high-dose comparison is more relevant for long-term comparison, high-dose therapy (irbesartan 300 mg/HCTZ 25 mg) would not be cost-effective with a 20% lower price for candesartan, and a threshold of h50 000 per QALY. In 55-year-old women with severe hypertension, 44 Tengs and Lin, 45 Kirsch and McGuire, 46 and our own calculations. Utilities for myocardial infarction assumed to be equal to angina utilities. Cost-effectiveness of irbesartan in combination with HCTZ M Ekman et al losartan would be dominated by irbesartan, whereas irbesartan in turn would be dominated by candesartan, that is, candesartan would have better health effects and lower cost with a 20% lower price both compared with low-dose and high-dose irbesartan therapy (however, see the discussion for a comment regarding the interpretation of these results).
Patent expiry. The patents of the ARBs will expire in the coming years, which will affect the costeffectiveness if a treatment duration of several years is simulated in the model. With a generic price for losartan from 2010 and onwards, and generic prices for other ARBs from 2012 and onwards, irbesartan was still dominant compared with valsartan in the base case. The cost-effectiveness ratio compared with losartan was h32 300 for men, which would still be considered as acceptable given a threshold of h50 000. For women, the cost-effectiveness ratio compared with losartan would be h151 800, which would exceed the h50 000 threshold. In the scenario with moderate-to-severe hypertension, irbesartan would still be cost-effective for men compared with losartan and candesartan, with cost-effectiveness ratios ranging from h10 800 compared with losartan to h22 000 compared with candesartan. For women with moderate-to-severe hypertension, the costeffectiveness ratios ranged from h43 600 for irbesartan compared with losartan to h122 000 for irbesartan compared with candesartan.
Treatment duration. In the base case, the duration of antihypertensive therapy was assumed to be 5 years. The cost-effectiveness was not very sensitive Abbreviations: HCTZ, hydrochlorothiazide; QALY, quality-adjusted life-year.
Patients with mild-to-moderate hypertension. Irbesartan/HCTZ 150/12.5 mg and irbesartan/HCTZ 300/25 mg.
Cost-effectiveness of irbesartan in combination with HCTZ M Ekman et al to the assumption regarding the duration of antihypertensive treatment in the model. For 55-yearold men, for example, the cost-effectiveness ratio went from h4100 per QALY with 2-year treatment duration to h3200 per QALY with 20-year treatment duration. This result was to be expected, as treatment costs, savings and health benefits increase in about equal proportion with time. Longer treatment duration gives more favourable cost-effectiveness than a shorter one, because the addition of QALYs is greater for a longer duration, which outweighs the greater costs that also are associated with longer treatment duration.
Starting age and discount rate. The age at which antihypertensive therapy is initiated (here called starting age) also plays an important role for the cost-effectiveness. At a discount rate of 3% for both costs and health effects, the cost-effectiveness ratio went from h15 000 per QALY gained for a 45-year-old male to h200 per QALY gained for an 85-year-old male. For elderly patients, the choice of discount rate has relatively little effect on the cost-effectiveness, whereas the effect is quite marked for younger age groups, because they accrue costs and health effects over a longer time period. For men aged 55, the costeffectiveness ratio went from h2300 per QALY with a discount rate of 0% to h7000 per QALY when both costs and health effects were discounted at 8%.
Life years gained. With all utilities set to one, the outcome measure is LYG instead of QALYs. This only had a small effect on the results, with a costeffectiveness ratio of h3190 per LYG compared with placebo in the base case (55-year-old men with mildto-moderate hypertension). Also in moderate-to-severe hypertension the cost-effectiveness results changed very little when LYG were used instead of QALYs.
Discussion
The economic evaluation was based on a decisionanalytic model of the costs and effects of BP lowering. The results showed that irbesartan was cost-effective compared with both placebo and to losartan and valsartan in patients with mild-tomoderate hypertension. In moderate-to-severe hypertension, irbesartan was cost-effective compared with losartan, but not compared with candesartan in women (due to higher reduction in SBP), or in men if the cost for high-dose irbesartan therapy was used.
The results for women are somewhat different from those for men, which is partly due to a lower prevalence of cardiovascular disease in any given age group, and partly due to the fact that only SBP was included in the risk equations for women derived by Glynn et al., 34 while the effect of DBP reduction was not significant.
The findings from the cost-effectiveness calculations show that even relatively small differences in BP reduction between angiotensin-II inhibitors may result in advantages in terms of cost-effectiveness. The differences in costs and effects between irbesartan, valsartan, losartan and candesartan are rather small; however, but this is to be expected as these three medications have similar prices and similar short-term BP reductions. Even so, the sensitivity analyses showed that the cost-effectiveness results were fairly stable for variations in most variables, with the exception of predicted price falls due to patent expiry. As was mentioned in the methods; however, all results have been calculated by predictive modelling on the basis of short-term clinical results rather than long-term observational data.
The base-case results of the long-term model were on a similar level as those reported for comparison with placebo by the Swedish Council on Technology Assessment in Health Care. 43 However, more data on the patients' quality of life in different cardiovascular health states were incorporated in this study, and more comprehensive cost data were also used. BP reduction in itself may not lead to increased quality of life, but by reducing the long-term risk of disease states that are associated with considerably depressed quality of life, for example, heart failure and stroke, the quality-of-life gains of antihypertensive therapy are substantial. The estimates of the risk reductions were taken from epidemiological studies in both analyses; the Framingham study in the report by the Swedish Council on Technology Assessment in Health Care, 43 and Glynn et al. 34 and SCORE 42 in the present analysis. Extra costs for consultations and travel of about h170 per year were included for antihypertensive treatment in the report by the Swedish Council on Technology Assessment in Health Care, but the inclusion of these cost in the present model would not change the results compared with placebo very much (only by a few hundred Euros), and the results comparing different antihypertensives would not be affected at all, as all ARB treatments would presumably be associated with the same costs for consultations and travel.
As a comparison with placebo is not relevant for clinical decision-making if treatment options are available, the economic evaluation was primarily based on a comparison with selected alternative antihypertensive agents, angiotension-II inhibitors losartan, valsartan and candesartan, which we believe to represent the most appropriate comparators in Swedish health-care settings. As there are few head-to-head clinical trials of these medications with irbesartan, it was necessary to use an indirect comparison of data from two or three different studies combined in the same model scenario.
The selection of studies was guided by the goals of the analyses, which were to study irbesartan and HCTZ vs other ARBs in combination with HCTZ. Comparisons between irbesartan and losartan in mild-to-moderate hypertension are available in, for example, Kassler-Taub et al., 47 Neutel and Smith 29 and Oparil et al. 48 For the base case analysis, the Neutel and Smith study was used here, even though the sample size is quite small (n ¼ 30). The study by Kassler and Taube did not include combination therapy and used only losartan 100 mg, and in Oparil et al. the patients were uptitrated as needed from losartan 50-100 mg or from irbesartan 150-300 mg, and HCTZ was added if the goals were not reached. This makes a direct dose comparison difficult. In the study by Neutel and Smith, the difference in BP reduction between irbesartan and losartan was statistically significant only for DBP (P ¼ 0.01), perhaps due to the small sample size. However, using the study by Neutel and Smith represents a conservative approach, as the BP reductions with irbesartan in this study are slightly more favourable compared with the BP reductions with irbesartan in Bobrie et al., 28 which means that the relative efficacy of irbesartan compared with losartan may be underestimated if the data concerning losartan from Neutel and Smith 29 are compared indirectly with the data for irbesartan in Bobrie et al.
28
A potential problem in the analysis of moderateto-severe hypertension was that all patients in Neutel et al. 30 were uptitrated to high-dose therapy, whereas the patients in Salerno et al. 31 were only uptitrated as needed to reach the DBP goal. However, only 12.5% of the patients on losartan 50 mg/ HCTZ 12.5 mg had reached the treatment goal after 2 weeks, which means that 87.5% were uptitrated to the higher dosage (losartan 100 mg/HCTZ 25 mg).
The INCLUSIVE study, which was used for the high-dose/low-dose comparison, was biased against high-dose therapy, because only patients who were not well controlled were uptitrated to 300/25 mg. 33 A head-to-head comparison in two arms would have been more appropriate for the cost-effectiveness analysis, but no such data are currently available for relevant dosage combinations. Since a majority of the patients were uptitrated to highdose therapy, the results are probably still fairly representative.
We did not include any comparisons with other classes of antihypertensive agents. Diuretics would for example be considered as suitable first-line treatment alternative in mild-to-moderate hypertension, unless the patients have specific indications such as heart failure, diabetes or chronic kidney disease. 3 We did not find any meta-analyses that were in line with the goals of the study. Conlin et al. 49 studied combination therapy with HCTZ, but did not include the most recent studies (published in year 2000), and Baguet et al. 50, 51 only studied monotherapy. The conclusion of Conlin et al. 49 was that antihypertensive efficacy was comparable within the ARB class, and that there was substantial increase of the antihypertensive effect with addition of HCTZ. Oparil et al. 52 compared olmesartan with losartan, valsartan and irbesartan, and found significantly greater BP reductions for olmesartan compared with losartan and valsartan, but not compared with irbesartan. Baguet et al. 50 found that among the major antihypertensive drug classes, BP reductions were most marked with diuretics. Elmfeldt et al. compared differences in placebo-adjusted maximal achievable effects in DBP between candesartan and losartan, valsartan and irbesartan, and found a significant effect at the 5% level for candesartan compared with valsartan, but not compared with losartan or irbesartan. 53 Although long-term data are currently not available from clinical trial evidence, it seems that, on the basis of a short-term comparison of representative patients with mild-to-moderate essential hypertension, even relatively small differences in BP reduction between angiotensin-II inhibitors may result advantages in terms of cost-effectiveness, under the assumption that those difference would be persistent over time. Irbesartan has a safety and tolerability profile that is very good, especially in certain groups, for example, elderly, obese and diabetic patients with hypertension, and can thus be regarded as a safe and cost-effective treatment choice for patients with hypertension in a broad range of patient groups. The results do not include patients with metabolic syndrome or diabetes, and no account was taken of end-stage renal disease due to diabetes in this model. For an appreciation of the potential benefits of irbesartan in diabetes, the reader is referred to other studies. 13, 54, 55 
